联环药业：目前有6个创新药

Core Viewpoint - The company currently has six innovative drugs in development, focusing on cardiovascular, urological, anti-tumor, and respiratory systems [1] Group 1: Innovative Drug Pipeline - The company has six innovative drugs, with one in Phase III, two in Phase I clinical trials, and three in preclinical research [1] - The drug LH-2103 is undergoing IIT (investigator-initiated trials) and DDI (drug-drug interaction) studies [1] - The drug LH-1801 is in Phase III, having completed patient enrollment for both monotherapy and combination therapy, with ongoing follow-up for both treatment types [1]